Clinical Trial: A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease (NPC)

U.S., July 25 -- ClinicalTrials.gov registry received information related to the study (NCT07082725) titled 'A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease (NPC)' on June 27.

Brief Summary: An 18-month double-blind, randomized, placebo-controlled, multicenter, Phase 3 study to evaluate the safety and efficacy of oral nizubaglustat (AZ-3102) in late-infantile and juvenile forms of Niemann-Pick type C disease

Study Start Date: June 30

Study Type: INTERVENTIONAL

Condition: Niemann-Pick Type C Disease

Intervention: DRUG: Nizubaglustat

AZ-3102

DRUG: Placebo

Matching placebo

Recruitment Status: RECRUITING

Sponsor: Azafaros A.G.

Published ...